The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Davis, k.
* Articles by Berger, P. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Davis, k.
* Articles by Berger, P. A.

Am J Psychiatry 1975; 132:951-953
Copyright © 1975 by American Psychiatric Association

REGULAR ARTICLES

Thyrotropin-releasing hormone in schizophrenia

kl Davis, LE Hossister and PA Berger

Oral administration of thyrotropin-releasing hormone (TRH) caused deterioration in the clinical status of seven out of nine schizophrenic men. This change was particularly apparent in the four patients diagnosed as paranoid schizophrenics. Such changes might be expected from a drug with properties similar to amphetamine.




Get information about faster international access.

Privacy Policy

Copyright © 1975 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org